Europe - FRA:TN8 - US8835561023 - Common Stock
Overall TN8 gets a fundamental rating of 5 out of 10. We evaluated TN8 against 19 industry peers in the Life Sciences Tools & Services industry. TN8 scores excellent on profitability, but there are some minor concerns on its financial health. TN8 is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 6.5% | ||
ROE | 13.04% | ||
ROIC | 6.25% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 18.18% | ||
PM (TTM) | 15.24% | ||
GM | 41.34% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | 5.71 | ||
Altman-Z | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.93 | ||
Quick Ratio | 1.5 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 21.77 | ||
Fwd PE | 19.34 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 29.17 | ||
EV/EBITDA | 19.29 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 0.35% |
FRA:TN8 (9/16/2025, 7:00:00 PM)
403.65
-0.95 (-0.23%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 0.35% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 21.77 | ||
Fwd PE | 19.34 | ||
P/S | 4.16 | ||
P/FCF | 29.17 | ||
P/OCF | 23.75 | ||
P/B | 3.57 | ||
P/tB | N/A | ||
EV/EBITDA | 19.29 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 6.5% | ||
ROE | 13.04% | ||
ROCE | 8.88% | ||
ROIC | 6.25% | ||
ROICexc | 6.74% | ||
ROICexgc | 28.04% | ||
OM | 18.18% | ||
PM (TTM) | 15.24% | ||
GM | 41.34% | ||
FCFM | 14.28% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | 5.71 | ||
Debt/EBITDA | 3.08 | ||
Cap/Depr | 49.03% | ||
Cap/Sales | 3.26% | ||
Interest Coverage | 250 | ||
Cash Conversion | 70.63% | ||
Profit Quality | 93.71% | ||
Current Ratio | 1.93 | ||
Quick Ratio | 1.5 | ||
Altman-Z | N/A |